Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
HealthCare Global Enterprises Limited (HCG) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of HealthCare Global Enterprises Limited ₹123, price ₹713, upside -82.8%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? No
- Add to watchlist
HG
Some data
Sep 24, 2026
HealthCare Global Enterprises Limited
HCG · BSEWeakest SetupStrongly overvalued and low quality.
!Fair value ₹122.73 · Strongly overvalued (−83%)
!Quality 36/100
!Mixed Growth (revenue 5y +20.4 %/yr)
!Thin margins · 0.9% net margin (TTM)
✓Low debt · generates free cash flow
!Narrow moat 25/100
!Evidence only medium, so the estimate is less certain
Watch HealthCare Global Enterprises Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹181.85 – ₹777.55 · fair‑value band ₹95.47 – ₹151.02 · the ₹712.90 price screens above the ₹122.73 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
HealthCare Global Enterprises Limited, together with its subsidiaries, provides medical and healthcare services focusing on cancer and fertility in India and internationally.
Show more
HealthCare Global Enterprises Limited, together with its subsidiaries, provides medical and healthcare services focusing on cancer and fertility in India and internationally. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates multi-specialty hospitals under the HCG brand that provides inpatient and outpatients treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care. In addition, the company offers cancer diagnostic services; combining laboratory services; and research and development, and clinical research to enhance cancer diagnosis and prognosis. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.
Stock analysis
HealthCare Global Enterprises Limited (HCG) currently trades at ₹712.90, while our model-based Fair Value estimate is ₹122.73, implying the stock looks roughly 480.7% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹291.72 per share, and 0 of the 23 models we run sit above the ₹712.90 price.
Bear case: the Earnings-Based group reads lowest at ₹14.50, and 23 of the 23 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹95.47 (bear) to ₹151.02 (bull), the price of ₹712.90 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
HealthCare Global Enterprises Limited reported revenue of ₹25.4B in FY2026 versus ₹13.8B in FY2022, a compound +16.4%/yr. Reported net income was ₹138M in FY2026, compounding −28.9%/yr from FY2022.
Key figures
Market cap ₹106B (≈ $1.1B) · P/E ratio 454.1 · P/S ratio 2.46 · EPS (TTM) ₹1.57 · Net margin 0.5% · Return on equity 1.9% · Return on assets (EBIT) 5.2% · Operating margin 7.5%.
What moves the price
The share trades about 11% below its 52-week high and 39% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −83%, HCG screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹14.50 to ₹548.61). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹95.47
Fair Value ₹122.73
Bull ₹151.02
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.7613 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
₹194.68
₹368.02
₹783.46
75
Growth DCF
₹189.62
₹386.20
₹694.72
75
EPV
₹119.76
₹140.42
₹158.50
74
All 23 models by family
DCF Models
FCF DCF
₹194.68
₹368.02
₹783.46
75
5Y Revenue Exit
₹151.64
₹281.48
₹464.36
70
5Y EBITDA Exit
₹272.77
₹548.61
₹915.76
72
5Y P/E Exit
₹65.83
₹92.25
₹119.90
71
10Y Revenue Exit
₹159.08
₹291.72
₹510.92
64
10Y EBITDA Exit
₹246.73
₹495.30
₹914.78
65
10Y P/E Exit
₹105.58
₹147.52
₹202.73
64
Earnings-Based
Graham-Dodd
₹6.27
₹36.01
₹50.08
63
Lynch FV
₹10.15
₹14.50
₹18.85
61
PEG = 1.0
₹10.15
₹14.50
₹18.85
57
EPV
₹119.76
₹140.42
₹158.50
74
Multiples
P/E Multiple
₹15.21
₹20.28
₹25.34
63
P/S Multiple
₹11.75
₹15.67
₹19.58
58
P/B Multiple
₹11.75
₹15.67
₹19.58
55
EV/EBIT
₹185.03
₹248.11
₹311.20
66
EV/EBITDA
₹323.35
₹432.54
₹541.73
67
EV/Revenue
₹130.85
₹188.74
₹246.63
53
Asset-Based
NCAV (Graham)
₹44.61
₹59.77
₹89.21
54
Growth DCF
Growth DCF
₹189.62
₹386.20
₹694.72
75
Rev-Margin DCF
₹151.64
₹276.90
₹450.73
71
Economic Profit
Residual Income
₹60.97
₹56.56
₹41.40
71
ROIC Compounder
₹137.86
₹201.92
₹269.37
71
Growth Earnings
Growth-Adj P/E
₹15.38
₹21.97
₹28.56
67
Notify me when HCG reaches fair value
Put HCG on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
36/100
Of which business quality 40 · Market factors (momentum, volatility) 68
Profitability
31
Margins and returns on capital today
Quality Growth
46
Are margins and returns improving?
Cashflow
44
Earnings quality: real cash, not paper profit
Fin. Strength
53
Balance sheet, leverage, solvency risk
Investment
24
Disciplined investing over empire-building
Low Volatility
82
Calm price path (market factor)
Momentum
67
Price trend over the last 3–12 months (market factor)
52W Momentum
56
Distance to the 52-week high (market factor)
Net Issuance
34
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
85/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+14.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.4%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.9%
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+28.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+28.3%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−3% → 9%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+70.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +63.5% a year for the price.
HCG screens 481% overvalued. Compare with HCA Healthcare, Inc →
Compare HealthCare Global Enterprises Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 261 stocks
Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $438.12 | $592.64 | +35% |
| Fresenius SE FRE | €45.57 | €34.54 | −24% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 227.50 SAR | 109.45 SAR | −52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.48 SGD | 1.63 SGD | −34% |
| Tenet Healthcare Corporation THC | $262.06 | $399.58 | +52% |
| DaVita Inc DVA | $183.72 | $255.97 | +39% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,836 | ₹2,908 | −67% |
| Fresenius Medical Care AG FME | €39.30 | €71.28 | +81% |
| Aier Eye Hospital Group 300015 | ¥8.07 | ¥10.86 | +35% |
| Encompass Health Corporation EHC | $122.76 | $96.51 | −21% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is HealthCare Global Enterprises Limited (HCG) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹122.73 versus a price of ₹712.90, about −83% upside (overvalued).
What is the fair value of HCG?
Our model-based fair value for HealthCare Global Enterprises Limited is ₹122.73 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹712.90.
What is the quality score of HCG?
HealthCare Global Enterprises Limited has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HealthCare Global Enterprises Limited (HCG)?
Our model-based price target is the fair value of ₹122.73 (as of Sep 24, 2026) from 23 valuation models. Cautious scenario ₹95.47, optimistic scenario ₹151.02. It is a calculation from audited fundamentals, not an analyst target.
What is the HealthCare Global Enterprises Limited stock forecast for 2026?
Our models put fair value at ₹122.73, about −83% upside versus a price of ₹712.90 (overvalued). Cautious scenario ₹95.47, optimistic scenario ₹151.02. The calculation is refreshed regularly with new filings.
What is the revenue of HealthCare Global Enterprises Limited (HCG)?
HealthCare Global Enterprises Limited reported trailing-twelve-month revenue of about ₹26.3B (latest available figure, as of Sep 24, 2026).
What growth is priced into HealthCare Global Enterprises Limited (HCG)?
For today's price to be fair in a discounted-cash-flow model, HealthCare Global Enterprises Limited would have to grow free cash flow by +70.2 % per year for five years (discount rate 13.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +20.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of HCG use?
Our models discount HealthCare Global Enterprises Limited at 13.9 %: a base by market capitalisation (small), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For HealthCare Global Enterprises Limited that is +70.2 % per year a year over ten years, using the same discount rate (13.9 %) and the same formula as our fair value.
How much growth has HealthCare Global Enterprises Limited (HCG) delivered so far?
Over the past 5 years revenue at HealthCare Global Enterprises Limited grew +20.4 % a year. The price currently implies +70.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of HealthCare Global Enterprises Limited (HCG) growing?
The median revenue growth in the sector is +4.1 % a year. That is the yardstick for the growth priced into HealthCare Global Enterprises Limited (+70.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of HealthCare Global Enterprises Limited (HCG)?
The free-cash-flow yield on the price is 0.52 %: that much free cash flow HealthCare Global Enterprises Limited produces per unit of market value. When it exceeds the discount rate of our models (13.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of HealthCare Global Enterprises Limited (HCG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HealthCare Global Enterprises Limited it is ₹122.73 per share (as of Sep 24, 2026), against a price of ₹712.90. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is HealthCare Global Enterprises Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, HCG trades above its calculated fair value: price ₹712.90, fair value ₹122.73, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HCG?
No. The price is what the market pays today (₹712.90); the fair value is what the company's own numbers justify (₹122.73). For HealthCare Global Enterprises Limited the two are ₹590.17 per share apart. That gap is exactly why we show both numbers side by side.
How much is HealthCare Global Enterprises Limited worth?
The market values HealthCare Global Enterprises Limited at about ₹106B (market capitalisation, as of Sep 24, 2026). Per share that is ₹712.90; our models calculate a fair value of ₹122.73 per share.
What do the bullish and bearish scenarios say about HCG?
Our models span a range for HealthCare Global Enterprises Limited: cautious scenario ₹95.47, base ₹122.73, optimistic ₹151.02 per share (as of Sep 24, 2026, price ₹712.90). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HCG?
HealthCare Global Enterprises Limited trades at a price-to-earnings ratio of 454.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹122.73 is built from several models across several years. Other multiples: P/B 8.2, P/S 4.2, EV/EBITDA 22.2.
How solid is the balance sheet of HealthCare Global Enterprises Limited (HCG)?
Balance-sheet figures for HealthCare Global Enterprises Limited (as of Sep 24, 2026): return on equity 1.9%, debt of 0.45 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is HCG from its 52-week high?
HealthCare Global Enterprises Limited trades at ₹712.90, about 11% below its 52-week high of ₹804.30 and 39% above the low of ₹513.40 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of ₹122.73 is for.
Which stocks are comparable to HealthCare Global Enterprises Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HealthCare Global Enterprises Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹712.90, calculated fair value ₹122.73 (−83%), Quality Score 36/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HCG calculated?
We run HealthCare Global Enterprises Limited through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹122.73, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. HealthCare Global Enterprises Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HealthCare Global Enterprises Limited (HCG)?
The closing price on Sep 22, 2026 was ₹712.90. Our model-based fair value is ₹122.73, about −83% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HealthCare Global Enterprises Limited right now?
The price sits above even our optimistic bull case (₹151.02). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of HealthCare Global Enterprises Limited
How large is the market capitalisation of HealthCare Global Enterprises Limited (HCG)?
The market capitalisation of HealthCare Global Enterprises Limited is ₹106B (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HealthCare Global Enterprises Limited (HCG)?
The price-to-sales ratio of HealthCare Global Enterprises Limited is 2.46 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of HealthCare Global Enterprises Limited (HCG)?
Earnings per share at HealthCare Global Enterprises Limited are ₹1.57 (price ÷ EPS = P/E 454.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of HealthCare Global Enterprises Limited (HCG)?
The net margin of HealthCare Global Enterprises Limited is 0.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HealthCare Global Enterprises Limited (HCG)?
The return on equity (ROE) of HealthCare Global Enterprises Limited is 1.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HealthCare Global Enterprises Limited (HCG)?
On an EBIT basis the return on assets of HealthCare Global Enterprises Limited is 5.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HealthCare Global Enterprises Limited (HCG)?
The operating margin of HealthCare Global Enterprises Limited is 7.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HealthCare Global Enterprises Limited (HCG)?
Revenue at HealthCare Global Enterprises Limited is growing +13.4% versus a year earlier (3y avg +14.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HealthCare Global Enterprises Limited (HCG)?
Earnings per share at HealthCare Global Enterprises Limited are growing +171% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does HealthCare Global Enterprises Limited (HCG) carry?
The net debt of HealthCare Global Enterprises Limited is ₹3.7B (fiscal year 2026, ≈ 6.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch HealthCare Global Enterprises Limited in the live analysis
One click puts HealthCare Global Enterprises Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.